• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Guardant Health Inc.

    6/17/25 4:01:58 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001336504
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Guardant Health, Inc.
    SEC File Number
    001-38683
    Address of Issuer
    3100 HANOVER STREET
    PALO ALTO
    CALIFORNIA
    94304
    Phone
    855-698-8887
    Name of Person for Whose Account the Securities are To Be Sold
    CLARK IAN T
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Charles Schwab & Co., Inc.
    3000 Schwab Way
    Westlake � TX � 76262
    6672322818.0012388804506/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/12/2025Restricted Stock LapseGUARDANT HEALTH, INC.Checkbox not checked667206/13/2025Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    The shares in this filing were sold in the Thornton-Clark Family Trust.
    Date of Notice
    06/17/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    IAN T CLARK TTEE

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $GH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/13/2023$27.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Guardant Health with a new price target

      Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

      4/10/25 12:41:47 PM ET
      $GH
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Guardant Health with a new price target

      Barclays initiated coverage of Guardant Health with a rating of Overweight and set a new price target of $60.00

      1/23/25 7:45:30 AM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health upgraded by Guggenheim with a new price target

      Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00

      6/28/24 7:41:07 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recomm

      6/10/25 7:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

      LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient's blood without the need for a tissue sample. The LIBERATE study retrospectively analyzed 29

      6/9/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that its Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). The Shield MCD test is a methylation-based blood test for the multi-cancer screening of multiple cancer types including bladder, colorectal, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer. The FDA grants Breakthrough Device designation to a limited set of qualifying devices that have the potential to provide for more effective treatment or diagnosis of life-threateni

      6/3/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    SEC Filings

    See more
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/18/25 5:00:29 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/17/25 4:01:58 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form 144 filed by Guardant Health Inc.

      144 - Guardant Health, Inc. (0001576280) (Subject)

      6/16/25 4:20:52 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      3/19/24 5:29:06 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Saia John G. covered exercise/tax liability with 535 shares and converted options into 1,020 shares, increasing direct ownership by 1% to 43,568 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      6/16/25 8:05:45 PM ET
      $GH
      Medical Specialities
      Health Care
    • Chief Information Officer Kalia Kumud converted options into 637 shares and covered exercise/tax liability with 228 shares, increasing direct ownership by 2% to 19,174 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      6/16/25 8:04:24 PM ET
      $GH
      Medical Specialities
      Health Care
    • Chief Commercial Officer Freeman Chris converted options into 6,281 shares and covered exercise/tax liability with 2,675 shares, increasing direct ownership by 8% to 46,757 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      6/16/25 8:03:04 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 30, 2024 - FDA Roundup: July 30, 2024

      For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

      7/30/24 3:38:18 PM ET
      $GH
      Medical Specialities
      Health Care
    • May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

      For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

      5/28/21 1:05:48 PM ET
      $AMGN
      $GH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
    • May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

      For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

      5/21/21 12:50:51 PM ET
      $JNJ
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities

    $GH
    Financials

    Live finance-specific insights

    See more
    • Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

      4/30/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Gua

      4/10/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa

      2/20/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Leadership Updates

    Live Leadership Updates

    See more
    • Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

      Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

      3/5/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Roberto A. Mignone Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

      10/24/24 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A

      7/18/24 5:00:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/13/24 7:34:17 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/8/24 10:46:38 AM ET
      $GH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

      SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

      7/5/24 10:32:48 AM ET
      $GH
      Medical Specialities
      Health Care